MDNA News and Press, Medicenna Therapeutics Corp. From 01/31/23

TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairm...

TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to r...

- Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT ™ TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenn...

- MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation - New data reaffirm MDNA11’s potential to overcome the major safety, pharmacokinetic, and pharmacody...

Medicenna Therapeutics Corp. (MDNA) Q2 2023 Earnings Conference Call November 04, 2022 08:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants David Martin ...

Medicenna Therapeutics press release ( NASDAQ: MDNA ): Q2 GAAP EPS of -$0.01 beats by $0.05 . Medicenna had cash, cash equivalents, and marketable securities of $40 million at September 30, 2022. These funds provide the Company with sufficient capital to execute its cu...

- Results from low and mid-dose escalation cohorts in Phase 1/2 ABILITY study show tumor control in 5 of 14 evaluable patients, including a confirmed partial response in pancreatic cancer - $40 million in cash, cash equivalents, and marketable securities at September 30, 2022, p...

Medicenna Therapeutics ( NASDAQ: MDNA ) received a notice from Nasdaq for not being in compliance with the $1 minimum bid price requirement for continued listing on the exchange. The company on Friday said that it has 180 calendar days, or until April 24, 2023, to...

TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the “Notice”) from the ...

TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, 2022 at 8:30 AM E...